Viren NMN Soni

Dr. Viren NMN Soni

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Akhil NagarAkhil Nagar
Akhil Nagar
DSDipayan Sarkar
Dipayan Sarkar
RBRuchita Bardiya
Ruchita Bardiya
ASAtul Shirkhedkar
Atul Shirkhedkar
VSViren NMN Soni
Viren NMN Soni
ATArindam Talukdar
Arindam Talukdar

VSViren NMN Soni
Viren NMN Soni
Akhil NagarAkhil Nagar
Akhil Nagar
RBRuchita Bardiya
Ruchita Bardiya
JMJacob Mara
Jacob Mara
LSLukas Von Suskil
Lukas Von Suskil
CSChetankumar Sonawane
Chetankumar Sonawane
Cancer stem cells (CSCs) are the cells in a primary tumor that have the opportunity to self-renew as well as differentiate into certain cell types, thus forming a mixed tumor. CSCs have been shown to be involved in every aspect of cancer development, including tumor initiation, proliferation, and metastatic activity; they are also involved in chemotherapeutic drug resistance and the recurrence of certain cancers. Based on these capabilities, CSCs have been explored as the next target for the treatment and management of cancer. Salinomycin (SAL), a polyether ionophore antibiotic being used in the poultry industry, was identified as a powerful anti-cancer compound that possesses broad-spectrum activities, especially against CSCs. Here we point out the noteworthy work reported on SAL’s mechanism of action, anticancer activities, toxicity, and clinic applications. In addition, SAL derivatives synthesized by different research groups and their biological activity will also be highlighted.

9 February 2026 in Polymers
Verified
Journal Article
Open access
PDF file
SDSanskruti Dave
Sanskruti Dave
VSViren NMN Soni
Viren NMN Soni
SSSamarth A. Shah
Samarth A. Shah
Walter KraftWalter Kraft
Walter Kraft
Gagan KaushalGagan Kaushal
Gagan Kaushal
Buprenorphine (BUP) is widely used in the treatment of neonatal opioid withdrawal syndrome (NOWS). However, the most compounded formulation contains 30% ethanol, despite regulatory and clinical concerns regarding ethanol exposure in pediatric patients. Thus, this research aimed to develop an ethanol-free sublingual (SL) gel formulation of BUP that would be safe, stable, and suitable for NOWS. Multiple polymers were screened as gelling agents, with hydroxypropyl methylcellulose (HPMC) emerging as the ideal base polymer for the formulation due to its optimal pH, rheological characteristics, and stability. The formulated gels were stored at room temperature and refrigerated conditions for 30 days and evaluated for stability using pH, rheology, and liquid chromatography-mass spectrometry. BUP content was between 90–110% of the labeled amount of the dosage form (75 µg/mL) at all time-points, and the pH remained close to physiological values. Release studies demonstrated a drug release of 23–24% for SL gels without surfactants stored at room temperature and refrigerated conditions, respectively. Incorporation of non-ionic surfactants (Tween 20 and Tween 80) significantly increased drug release to 33% and 40%, respectively, reflecting enhanced solubilization and improved mucosal penetration. The ethanol-free formulation demonstrated physicochemical stability and favorable release characteristics suitable for neonatal administration. These findings represent a meaningful advance in the development of safer pediatric formulations for NOWS.